Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma ( Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA )

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYLYNK-007 trial for advanced solid tumours ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in...

Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib ( Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA )

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...

Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase...

Prof Jorge Cortes - Augusta University, Augusta, USA

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia ( Prof Jorge Cortes - Augusta University, Augusta, USA )

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute...

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )

AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory...

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

$AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )$

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

$CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )$

More from ecancer